论文部分内容阅读
目的观察紫杉醇脂质体联合卡铂治疗非小细胞肺癌的临床疗效,并总结经验。方法 32例患者给予紫杉醇脂质体联合卡铂治疗作为治疗组,对既往28例患者给予紫杉醇联合卡铂治疗进行回顾性分析作为对照组,比较两组疗效以及并发症。结果治疗组与对照组相比有效率无显著差异,血液学毒性以及消化道反应等项目无显著差异,周围神经炎以及过敏反应项目治疗组显著低于对照组。讨论紫杉醇脂质体联合卡铂与紫杉醇联合卡铂治疗非小细胞肺癌疗效相当,但其毒副反应发生率显著降低,更为安全,可以改善化疗患者的生活质量,提高患者的依从性。
Objective To observe the clinical efficacy of paclitaxel liposome combined with carboplatin in the treatment of non-small cell lung cancer and to summarize the experience. Methods 32 patients were treated with paclitaxel liposomes combined with carboplatin as a treatment group. 28 patients were treated with paclitaxel combined with carboplatin for retrospective analysis as a control group. The curative effect and complication were compared between the two groups. Results Compared with the control group, there was no significant difference in the effective rate between the treatment group and the control group. There was no significant difference in the hematological toxicity and gastrointestinal reactions between the treatment group and the control group. The treatment group with peripheral neuritis and allergic reaction was significantly lower than the control group. Discussion paclitaxel liposomes combined with paclitaxel and carboplatin paclitaxel in the treatment of non-small cell lung cancer is quite effective, but the incidence of toxic reactions was significantly reduced, safer, can improve the quality of life of patients with chemotherapy and improve patient compliance.